We came across a bullish thesis on GRAIL, Inc. on Valueinvestorsclub.com by skimmer610. In this article, we will summarize the bulls’ thesis on GRAL. GRAIL, Inc.'s share was trading at $32.42 as of September 3rd. Veracyte (VCYT) Soars 7% on S&P SmallCap 600 Inclusion Photo by National Cancer Institute on Unsplash GRAIL (NASDAQ: GRAL) represents a compelling risk-reward opportunity in early cancer detection through its Galleri blood test, the first commercially viable multi-cancer early detection (MCED) ...